Literature DB >> 19272274

Is there a therapeutic window with some antidepressants for analgesic response?

J Hampton Atkinson1, Shetal M Patel, Jonathan M Meyer, Mark A Slater, Sidney Zisook, Edmund Capparelli.   

Abstract

Most antidepressants and anticonvulsants used in chronic pain syndromes have dose- and concentration-response curves developed for their application to treat psychiatric disorders. Because these are important clinical tools in medication management of psychiatric syndromes, it is reasonable to expect that utilizing concentration-effect relationships and known sources of pharmacokinetic variability for determining doses for analgesia may also improve treatment tolerability and outcomes. Efforts to identify dosing "therapeutic windows" or minimum "thresholds" for analgesic efficacy have provided useful guidance for initiating treatment, reducing toxicity, and assisting with decision making in the face of limited therapeutic response. This article reviews the strengths, limitations, and potential of therapeutic drug monitoring of antidepressants and anticonvulsants as analgesics for selected chronic pain syndromes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19272274     DOI: 10.1007/s11916-009-0018-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  32 in total

1.  A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Authors:  Lesley M Arnold; Amy Rosen; Yili Lu Pritchett; Deborah N D'Souza; David J Goldstein; Smriti Iyengar; Joachim F Wernicke
Journal:  Pain       Date:  2005-11-17       Impact factor: 6.961

2.  Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.

Authors:  H Lesser; U Sharma; L LaMoreaux; R M Poole
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

3.  Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.

Authors:  S H Sindrup; F W Bach; C Madsen; L F Gram; T S Jensen
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

4.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

5.  Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared.

Authors:  N Ward; J A Bokan; M Phillips; C Benedetti; S Butler; D Spengler
Journal:  J Clin Psychiatry       Date:  1984-03       Impact factor: 4.384

6.  Imipramine treatment of painful diabetic neuropathy.

Authors:  B Kvinesdal; J Molin; A Frøland; L F Gram
Journal:  JAMA       Date:  1984-04-06       Impact factor: 56.272

7.  Amitriptyline, but not lorazepam, relieves postherpetic neuralgia.

Authors:  M B Max; S C Schafer; M Culnane; B Smoller; R Dubner; R H Gracely
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

8.  Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.

Authors:  Michael C Rowbotham; Veeraindar Goli; Nadia R Kunz; Dean Lei
Journal:  Pain       Date:  2004-08       Impact factor: 6.961

9.  Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.

Authors:  David G Armstrong; Amy S Chappell; Trong K Le; Daniel K Kajdasz; Miroslav Backonja; Deborah N D'Souza; James M Russell
Journal:  Pain Med       Date:  2007 Jul-Aug       Impact factor: 3.750

10.  Using chronic pain to predict depressive morbidity in the general population.

Authors:  Maurice M Ohayon; Alan F Schatzberg
Journal:  Arch Gen Psychiatry       Date:  2003-01
View more
  1 in total

Review 1.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.